Focus on Asthma Care

Back to articles

Roflumilast: Promising Candidate for Asthma, COPD

KEY POINT

Clinical trials show that an investigational phosphodiesterase 4 (PDE4) inhibitor improves symptoms in two important groups: those with asthma and patients with chronic obstructive pulmonary disorder (COPD). If approved for marketing, roflumilast (Daxas) would be an important new product for the German developer, Altana Pharma. However, an agreement to codevelop Daxas with Pfizer was terminated on July 1, creating some uncertainty as to how far Altana will take the product in the United States as well as other parts of the world.

SOURCES

 

van Schalkwyk E et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol. 2005;116:292–8.

Rabe KF et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563–71.